Contact us

China National Pharmaceutical
Group Corporation(SINOPHARM)
Address: No.20 Zhichun
Road, Haidian District, Beijing, China
Postal Code: 100191
Tel:86-10-82287727
Fax: 86-10-62033332
Website: http://www.sinopharm.com

 

Learn more >>

Sinopharm News

Sinopharm Investment Attend CHIPS as Supporting Company

Post Time:2018-05-04 [Large Middle Small] View:

From March 15th to 17th, 2018 China Healthcare Investment & Partnering Symposium (CHIPS) was held in Hangzhou by TPP Healthcare and B. Riley FBR. China National Pharmaceutical Investment Co., Ltd. (Sinopharm Investment) attended the symposium as invited supporting company.

More than 50 biopharmaceutical and medical instrument companies were invited to carry out roadshows by the symposium. Both domestic and foreign enterprises talked with investment banks one-for-one and vis-a-vis. More than 1000 Chinese pharmaceutical enterprises got active and direct touch with foreign counterparts.

As an investing and financing company in the healthcare industry, Sinopharm Investment positions itself with the mission of focusing on healthcare and serving SINOPHARM business. And guided by the Department of International Cooperation and Department of Industry and R&D Management, Sinopharm Investment played an active role by inviting 25 colleagues from Sinopharm Holding, Sinopharm Biotec, Sinopharm Foreign Trade, Sinopharm Zhijun, Sinopharm A-think, Sinopharm Capital, Sinopharm Marketing and Shanghai Innostar to participate in the symposium. Many companies fully communicated and reached primary cooperation intent in terms of technology and capital with foreign enterprises.

Organizing the attending this symposium witnessed communication between Sinopharm companies and excellent foreign innovative pharmaceutical enterprises and investment intuitions which laid a sound foundation for obtaining good projects in the future, and also a favorable attempt to bridge accommodation of funds and project cooperation within and outside Sinopharm. Sinopharm influence got once again enhanced. (Reported by Sinopharm Investment)